#High-Throughput Screening forecast | Explore Tumblr posts and blogs

govindhtech · 6 months ago

Text

MediaTek Dimensity 9300+: Experience Next-Level Performance

MediaTek Dimensity 9300+

All-Big-Core Processor: Superior Performance With the MediaTek Dimensity 9300+, Arm Cortex-X4 speeds are increased to unprecedented heights, setting a new standard for smartphone performance for enthusiasts and gamers.

1X Cortex-X4 operating at 3.4 GHz Max. 3X Cortex-X4 2.85GHz Up to 2.0GHz, 4X Cortex-A720 18 MB L3 + SLC cache Supported up to LPDDR5T 9600Mbps MCQ plus UFS 4.0 Third generation of TSMC 4nm chips manufactured MediaTek’s second-generation thermally optimised packaging design Premier Generative AI System in MediaTek Dimensity 9300+

Faster and safer edge computing is made possible by the MediaTek APU 790 generative AI engine. MediaTek Dimensity 9300+ first-to-market features and extensive toolchain help developers create multimodal generative AI applications at the edge quickly and effectively, offering consumers cutting-edge experiences with generative AI for text, photos, music, and more.

Assistance with on-device NeuroPilot LoRA Fusion 2.0 and LoRA Fusion With NeuroPilot Speculative Decode Acceleration and ExecutorTorch Delegation support, performance can increase by up to 10%. Gen-AI partnerships Artificial Intelligence Cloud Alibaba Qwen LLM AI Baichuan ERNIE-3.5-SE Google Gemini Nano Llama 2 and Llama 3 Meta Epic Play

Flagship GPU with 12 cores Experience the most popular online games in HDR at 90 frames per second, while using up to 20% less power than other flagship smartphone platforms.

Adaptive gaming technology from MediaTek Activate MAGT to increase power efficiency in well-known gaming titles. This will allow top titles to run smoothly for up to an hour.

Experience the most popular online games in HDR at 90 frames per second, while using up to 20% less power than other flagship smartphone platforms.

Mobile Raytracing accelerated via hardware The Immortalis-G720 offers gamers quick, immersive raytracing experiences at a fluid 60 frames per second along with console-quality global lighting effects thanks to its 2nd generation hardware raytracing engine.

HyperEngine from MediaTek: Network Observation System (NOS)

Working with top game companies, MediaTek HyperEngine NOS offloads real-time network connectivity quality assessment, allowing for more efficient and power-efficient Wi-Fi/cellular dual network concurrency during gameplay.

Accurate Network Forecasting 10% or more in power savings Save up to 25% on cellular data guarantees a steady and fluid connection for internet gaming. Working along with Tencent GCloud Amazing Media Capture in All Situations The Imagiq 990 boasts zero latency video preview, AI photography, and 18-bit RAW ISP. Utilise its 16 categories of scene segmentation modification and AI Semantic Analysis Video Engine for more visually stunning cinematic video capture.

With three microphones capturing high dynamic range audio and filtering out background noise and wind, you can be heard clearly. This makes it perfect for impromptu vlogging.

AI-displayed MediaTek MiraVision 990 Set your goals on faster, sharper screens, and take advantage of the newest HDR standards and AI improvements for next-generation cinematic experiences.

Amazing displays: 4K120 or WQHD 180Hz AI depth finding Support that folds and has two active screens The best anti-burn-in technology available for AMOLED screens Maximum Interconnectedness WiFi 7 Extended Range Connections can extend up to 4.5 metres indoors thanks to MediaTek Xtra Range 2.0 technology (5GHz band). Up to 200% throughput improvement is provided for smoother graphics while streaming wirelessly to 4K Smart TVs thanks to coexistence and anti-interference technologies. UltraSaver Wi-Fi 7 MediaTek Wi-Fi 7 with Multi-Link Operation (MLO) and 320MHz BW up to 6.5Gbps Top Bluetooth Features Wi-Fi/BT Hybrid Coexistence 3.0 by MediaTek UltraSave Bluetooth LightningConnect MediaTek Extremely low Bluetooth audio latency (<35 ms) Smooth sub-6GHz with a 5G AI modem Sub-6GHz capable 4CC-CA 5G R16 modem Dedicated sub-6GHz downlink speed of up to 7 Gbps Modern AI equipped with situation awareness Dual SIM, Dual Active, Multimode 3.0 for MediaTek 5G UltraSave Outstanding Security for a Flagship SoC for Android

Introducing a user-privacy-focused security design that safeguards critical processes both during secure computing and boot-up, preventing physical attacks on data access.

During startup and operation, standalone hardware (Secure Processor, HWRoT) is used with New Arm Memory Tagging Extension (MTE) technology.

The next big thing in innovation is generative AI MediaTek Dimensity 9300+, the industry leader in creating high-performing and power-efficient system-on-chips, is already integrating the advantages of their potent, internally developed AI processors into their wide range of product offerings.

Every year,their inventions impact over 2 billion devices Fifth-largest fabless semiconductor maker MediaTek. MediaTek chips power 2 billion devices annually; you undoubtedly have one! Here at MediaTek, they design technology with people in mind to improve and enrich daily existence.

Amazing In Amazing Escape Smartphones with MediaTek Dimensity – 5G The cutting edge is available on MediaTek Dimensity 5G smartphone platforms, which offer amazing nonstop gaming, sophisticated AI, and professional-grade photography and multi-camera videography. Together, they enhance the intelligence, potency, and efficiency of your experience.

Chromebooks, the ubiquitous computing companion from MediaTek Kompanio MediaTek Kompanio is the dependable, creative, versatile, go-anywhere, and do-anything partner for amazing Chromebook experiences. It’s the perfect partner for learning, daily work, streaming media, video conferences, or just experimenting with one’s creativity.

MediaTek provides you with all you need in terms of computing. MediaTek processors are made to meet the needs of the modern user, whether they be for gaming, streaming, work, or education.

Brilliance on the brink IoT with Edge-AI with MediaTek Genio MediaTek Dimensity 9300+ Genio propels IoT innovation by elevating software platforms that are simple to use and have strong artificial intelligence. MediaTek helps start-ups to multinational corporations creating new IoT devices with Edge-AI capabilities, accelerating time to market to create new opportunities.

Entrepreneurs with a Vision: MediaTek Pentonic – 8K/4K Smart Televisions Five key technology pillars are offered by MediaTek Pentonic in their flagship and premium 8K/4K smart TVs: display, audio, AI, broadcasting, and connectivity. With a 60% global TV market share,they are the leading provider of smart TV platforms, supporting the largest smart TV brands in the world.

Experiences that are always connected Wi-Fi MediaTek Filogic With the most extreme speeds, improved coverage, built-in security, exceptional power efficiency, and crucial EasyMesh certification, MediaTek Filogic is bringing in a new era of smarter, more powerful Wi-Fi 7, 6E, and 6 solutions. These solutions will enable users to enjoy seamless, always-connected experiences.

MediaTek Dimensity 9300+ Specs CPU Processor 1x Arm Cortex-X4 up to 3.4GHz 3x Arm Cortex-X4 up to 2.85GHz 4x Arm Cortex-A720 up to 2.0GHz Cores Octa (8)

Memory and Storage Memory Type LPDDR5X LPDDR5T Max Memory Frequency 9600Mbps

Storage Type UFS 4 + MCQ

Connectivity Cellular Technologies Sub-6GHz (FR1), mmWave (FR2), 2G-5G multi-mode, 5G-CA, 4G-CA, 5G FDD / TDD, 4G FDD / TDD, TD-SCDMA, WDCDMA, EDGE, GSM

Specific Functions 5G/4G Dual SIM Dual Active, SA & NSA modes; SA Option2, NSA Option3 / 3a / 3x, NR FR1 TDD+FDD, DSS, FR1 DL 4CC up to 300 MHz 4×4 MIMO, FR2 DL 4CC up to 400MHz, 256QAM FR1 UL 2CC 2×2 MIMO, 256QAM NR UL 2CC, R16 UL Enhancement, 256QAM VoNR / EPS fallback

GNSS GPS L1CA+L5+ L1C BeiDou B1I+ B1C + B2a +B2b Glonass L1OF Galileo E1 + E5a +E5b QZSS L1CA+ L5 NavIC L5 Wi-Fi Wi-Fi 7 (a/b/g/n/ac/ax/be) ready

Wi-Fi Antenna 2T2R

Bluetooth 5.4

Camera Max Camera Sensor Supported 320MP

Max Video Capture Resolution 8K30 (7690 x 4320) 4K60 (3840 x 2160) Graphics GPU Type Arm Immortalis-G720 MC12

Video Encoding H.264 HEVC Video Playback H.264 HEVC VP-9 AV1 Display Max Refresh Rate 4K up to 120Hz WQHD up to 180Hz AI AI Processing Unit MediaTek APU 790 (Generative AI)

Security Security Features Secure Processor, HWRoT Arm Memory Tagging Extension (MTE) Technology CC EAL4+ Capable, FIPS 140-3, China DRM

Read more on Govindhtech.com

#MediaTekDimensity9300 #mediatek #MediaTekDimensity #ai #generativeai #llama2 #smartphone #lorafution #llm #llama3 #meta #technology #technews #news #govindhtech

3 notes · View notes

healthacare-insights · 4 hours ago

Link

0 notes

insightsbyskyquest · 7 hours ago

Text

DNA Sequencing Market Size, Share, Growth Analysis 2031

The DNA sequencing market has experienced remarkable growth in recent years and is expected to continue expanding rapidly in the coming decade. With advancements in genomics and biotechnology, DNA sequencing technologies have become indispensable in fields like medicine, agriculture, forensic science, and evolutionary biology. The increasing demand for personalized medicine, coupled with the growing focus on precision diagnostics and genomic research, has created a robust market environment for DNA sequencing.

The global DNA sequencing market was valued at USD 12.29 billion in 2023 and is projected to reach USD 44 billion by 2031, growing at a compound annual growth rate (CAGR) of approximately 17.12% during the forecast period from 2024 to 2031. This growth can be attributed to various factors, including the declining costs of sequencing, increasing applications across research and clinical settings, and rising investments in genomic research.

To Learn More About This Report, Request a Free Sample Copy - https://www.skyquestt.com/sample-request/dna-sequencing-market

Key Market Drivers

1. Advancements in Sequencing Technology: Next-generation sequencing (NGS) has revolutionized genomics by providing faster, cheaper, and more accurate sequencing solutions compared to traditional methods. Innovations in high-throughput sequencing technologies such as Illumina's platforms, Oxford Nanopore Technologies, and PacBio's Sequel System are pushing the boundaries of DNA sequencing, enabling researchers and clinicians to perform detailed genomic analyses in real time.

2. Growing Demand for Personalized Medicine: Personalized or precision medicine aims to tailor medical treatments based on an individual's genetic makeup. With DNA sequencing, clinicians can identify genetic mutations, predict disease susceptibility, and design individualized treatment regimens. The rapid growth in genetic testing for personalized healthcare, particularly in oncology, is driving the demand for sequencing services.

3. Rising Incidences of Genetic Disorders: The prevalence of genetic disorders, along with the increasing incidence of cancer and rare diseases, has driven the demand for genetic testing and diagnostics. DNA sequencing helps identify the underlying genetic causes of many diseases, leading to better diagnostics and therapies.

4. Decreasing Costs of Sequencing: The cost of sequencing a human genome has dramatically decreased over the past decade. The Human Genome Project (which completed in 2003) cost an estimated $2.7 billion to sequence a human genome. Today, with NGS technologies, it costs a few hundred dollars, making it accessible for both research institutions and clinical settings. This affordability has propelled the widespread use of DNA sequencing across various industries.

5. Government Initiatives and Investments: Governments worldwide are investing heavily in genomics research and healthcare infrastructure. For example, initiatives like the All of Us Research Program in the United States and Genomics England aim to build comprehensive genomic datasets, further accelerating the demand for DNA sequencing services.

Market Segmentation

The DNA sequencing market can be segmented based on technology, application, end-user, and region.

1. By Technology

- Next-Generation Sequencing (NGS): NGS dominates the market due to its high throughput, accuracy, and cost-effectiveness. It is used in a wide array of applications, including cancer genomics, genetic screening, and microbiome research.

- Sanger Sequencing: Although older and slower than NGS, Sanger sequencing is still used for smaller-scale projects and applications requiring high accuracy.

- Third-Generation Sequencing (TGS): TGS technologies, such as Oxford Nanopore and PacBio, provide long-read sequencing that allows for better analysis of structural variations and more comprehensive sequencing of complex genomes.

2. By Application

- Research Applications: DNA sequencing is widely used in genetic research, functional genomics, and evolutionary studies. It plays a critical role in discovering new biomarkers, understanding gene function, and exploring the genetic basis of diseases.

- Clinical Diagnostics: DNA sequencing is increasingly being used for diagnostic purposes, particularly for detecting genetic mutations in conditions like cancer, cardiovascular diseases, and rare genetic disorders.

- Agriculture & Animal Genomics: DNA sequencing is pivotal in enhancing crop yield, improving livestock breeding, and studying animal diseases.

- Forensic Science: DNA sequencing is a crucial tool in forensic investigations for identifying individuals, solving crimes, and establishing familial relationships.

3. By End-User

- Research Institutes and Academic Centers: These organizations conduct extensive genomic research and often lead the way in developing and implementing new DNA sequencing technologies.

- Hospitals & Diagnostic Laboratories: Hospitals use DNA sequencing to diagnose genetic diseases and tailor treatment plans for patients based on their genetic information.

- Biotechnology and Pharmaceutical Companies: These companies use sequencing to discover new drug targets, develop personalized therapies, and conduct clinical trials.

- Agricultural & Environmental Organizations: Genomic sequencing is used for improving agricultural products and monitoring environmental impacts.

Competitive Landscape

Key players in the DNA sequencing market include: Illumina, Inc., Thermo Fisher Scientific, Inc., Pacific Biosciences of California Inc., BGI Group, Oxford Nanopore Technologies Ltd., Qiagen N.V., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies, Inc., Eurofins Scientific SE, Zymo Research Corp., Hamilton Company, Genewiz Inc., Macrogen Inc., DNASTAR Inc., GENEWORLD, Bio-Rad Laboratories Inc., BioChain Institute Inc., Beckman Coulter Inc., Novogene Corporation

Read DNA Sequencing Market Report Today - https://www.skyquestt.com/report/dna-sequencing-market

The DNA sequencing market is poised for significant growth, driven by technological advancements, increasing demand for personalized medicine, and expanding applications in research and diagnostics. While challenges such as data management and regulatory hurdles exist, the market's future is bright, particularly with ongoing innovations in sequencing technologies and declining costs. As the global healthcare landscape continues to evolve, DNA sequencing will undoubtedly play an even more critical role in shaping the future of medicine, research, and diagnostics.

0 notes

insightfulblogz · 3 days ago

Text

Microplate Reader Market Revenue, Segments, Analysis and Forecasts 2032

A microplate reader is an essential laboratory instrument used for detecting chemical, biological, or physical events in microplate format. It enables researchers to analyze multiple samples simultaneously, providing critical data in areas such as enzyme-linked immunosorbent assay (ELISA), cell viability assays, DNA/RNA quantification, and protein analysis. With its ability to process high-throughput assays, the microplate reader has become a staple in drug discovery, biotechnology research, and clinical diagnostics, facilitating rapid data collection with high accuracy and reproducibility.

The Microplate Reader Market size was estimated at USD 486.89 million in 2023 and is expected to reach USD 941.32 million by 2032 at a CAGR of 7.6% during the forecast period of 2024-2032.

Future Scope

The future of microplate readers lies in their integration with automation, advanced optics, and artificial intelligence (AI) for enhanced sensitivity and versatility. Emerging models are incorporating AI-driven software to process data more quickly and accurately, while automated plate handling systems allow for continuous, unattended operation. Additionally, the adoption of multiplexing technology, which enables simultaneous detection of multiple analytes, will broaden applications in complex biological studies. This evolution will support cutting-edge research in precision medicine, genomics, and high-throughput screening.

Trends

Recent trends in microplate readers include the adoption of fluorescence and luminescence detection methods, miniaturization for lab-on-a-chip applications, and cloud-based data storage solutions. Enhanced fluorescence and luminescence capabilities enable more sensitive measurements, expanding the scope of applications in cellular and molecular assays. Miniaturization allows labs to conduct assays with minimal sample volumes, reducing costs and conserving resources. Cloud storage integration also enables remote data access and collaborative research, which has gained traction with the rise of decentralized research initiatives.

Applications

Microplate readers are widely used in fields such as drug discovery, clinical diagnostics, environmental testing, and food safety. In drug discovery, they streamline high-throughput screening processes to identify promising drug candidates. Clinical laboratories utilize microplate readers for diagnostics, such as hormone and infectious disease testing. Environmental labs employ them to monitor pollutants and contaminants, while the food industry uses them to test for allergens and pathogens, ensuring compliance with regulatory standards.

Key Points

Microplate readers enable high-throughput sample analysis in multiple scientific fields.

Future advancements include automation, AI integration, and multiplexing capabilities.

Trends focus on enhanced fluorescence and luminescence detection, miniaturization, and cloud-based data storage.

Applications span drug discovery, clinical diagnostics, environmental testing, and food safety.

Essential for rapid, accurate data collection in laboratory settings.

Conclusion

Microplate readers play a critical role in modern laboratories by providing an efficient solution for high-throughput sample analysis across diverse applications. As technology advances, microplate readers will become even more versatile, precise, and automated, supporting a wide range of scientific discoveries and healthcare solutions. Through innovations in detection methods and data management, these instruments are set to remain fundamental to biological research, diagnostics, and industrial quality control.

Read More Details: https://www.snsinsider.com/reports/microplate-reader-market-3866

Akash Anand — Head of Business Development & Strategy

Email: [email protected]

Phone: +1–415–230–0044 (US) | +91–7798602273 (IND)

#Microplate Reader Market #Microplate Reader Market Size #Microplate Reader Market Share #Microplate Reader Market Growth

0 notes

jayanthitbrc · 5 days ago

Text

Global Reporter Gene Assay Market Analysis 2024: Size Forecast and Growth Prospects

The reporter gene assay global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Reporter Gene Assay Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The reporter gene assay market size has grown strongly in recent years. It will grow from $5.88 billion in 2023 to $6.39 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to rising demand for cell-based assays, rise in genomics research, increased drug discovery and development research, rising need for personalized treatment, and demand for early diagnosis.

The reporter gene assay market size is expected to see strong growth in the next few years. It will grow to $9.03 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to the rising prevalence of chronic genetic disorders, growing demand for personalized medicine, growing use of molecular imaging systems, expansion of gene therapy portfolios, and government initiatives. Major trends in the forecast period include technological advancements in gene therapy, advancements in molecular biology, demand for advanced molecular diagnostic tools, shift towards 3d cell culture models, and strategic partnerships

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/reporter-gene-assay-global-market-report

Scope Of Reporter Gene Assay Market The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Reporter Gene Assay Market Overview

Market Drivers - The increasing drug discovery and development research is expected to propel the growth of the reporter gene assay market. Drug discovery and development research refers to the systematic process within the medical, biotechnology, and pharmacology fields that leads to identifying, creating, and introducing new medications to the market. The increasing drug discovery and development research is due to advancements in proteomics, high-throughput screening, genomics, and novel medications' successful development and approval. Reporter gene assays serve as valuable tools in discovery and development research, enabling researchers to gain insights into gene regulation, identify potential drug targets, screen compound libraries, and evaluate the efficacy and safety of candidate drugs. For instance, in April 2024, according to the Office for National Statistics, a UK-based government department, the UK government's net expenditure on research and development (R&D) rose to £15.5 billion ($19.7 billion) in 2022 from £14.0 billion ($17.8 billion) in 2021, an increase of 10.5%. Therefore, increasing drug discovery and development research is driving the growth of the reporter gene assay market.

Market Trends - Major companies operating in the reporter gene assay market are focusing on developing innovative solutions, such as ultrasensitive multiplexed digital PCR assays, to strengthen their position in the market. Ultrasensitive multiplexed digital PCR (dPCR) assays precisely detect and quantify nucleic acids by partitioning the sample into thousands or millions of individual reactions, each containing minute amounts of target DNA or RNA molecules. For instance, in April 2024, Bio-Rad Laboratories Inc., a US-based life science research company, launched the ddPLEX ESR1 Mutation Detection Kit, the first ultrasensitive multiplexed digital PCR assay. This new ultrasensitive multiplexed digital PCR assay for breast cancer mutation detection excels in sensitivity, detecting minute mutations in complex samples for early and precise disease monitoring. Its multiplexing feature enables simultaneous detection of multiple mutations, simplifying testing. This groundbreaking assay promises to revolutionize breast cancer research and personalized treatment strategies.

The reporter gene assay market covered in this report is segmented –

1) By Product: Assay Kits, Reagents 2) By Application: Promoter Structural And Functional Analysis, Cell Signaling Pathways, Protein Interaction, Clinical And Gene Regulation 3) By End-User: Biotechnology And Pharmaceutical Companies, Research And Academic Institutes, Hospital And Diagnostic Laboratories, Contract Research Organizations

Get an inside scoop of the reporter gene assay market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=16526&type=smp

Regional Insights - North America was the largest region in the reporter gene assay market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the reporter gene assay market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies - Major companies operating in the reporter gene assay market are <b>Roche Diagnostics, Thermo Fisher Scientific, Danaher Corporation, Merck KGaA, Becton Dickinson and Company (BD Biosciences), GE Healthcare, Lonza Group, Agilent Technologies, Sartorius AG, PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., GenScript Biotech Corporation, Abcam plc, Promega Corporation, Promega Corporation, Takara Bio Inc., New England Biolabs (NEB), OriGene Technologies Inc., Cell Signaling Technology Inc., SABiosciences, Enzo Biochem Inc., InvivoGen, Biotium Inc., Enzo Life Sciences Inc., BioAssay Systems, Indigo Biosciences Inc.</b>

Table of Contents 1. Executive Summary 2. Reporter Gene Assay Market Report Structure 3. Reporter Gene Assay Market Trends And Strategies 4. Reporter Gene Assay Market – Macro Economic Scenario 5. Reporter Gene Assay Market Size And Growth ….. 27. Reporter Gene Assay Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: [email protected]

Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

0 notes

marketanalysisdata · 5 days ago

Text

Blood Screening Market Emerging Trends, Analysis and Forecasts 2030

The global blood screening market was valued at USD 3.40 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 11.9% from 2025 to 2030. This growth is primarily driven by an increasing number of blood donations worldwide, which requires stringent screening protocols to prevent the transmission of infections through transfusions. Technological advancements, particularly in automation and molecular diagnostic platforms, have improved both the efficiency and accuracy of blood screening processes. Additionally, the rising prevalence of infectious diseases and government-backed initiatives promoting blood safety contribute to this market expansion. There is also growing public awareness about the importance of safe blood transfusions, which further supports market growth.

Blood screening is an essential medical process in which blood samples are analyzed to identify health conditions and potential abnormalities. This diagnostic tool provides crucial insights into a person’s health status, helping detect, prevent, and manage various diseases at an early stage. Blood screening involves assessing blood cell counts, identifying infectious agents like viruses and bacteria, and measuring specific chemical levels, such as cholesterol and glucose. The value of blood screening lies in its ability to allow healthcare providers to detect health issues before symptoms become evident, making it a critical tool for diagnosing conditions such as anemia, diabetes, infections, and cardiovascular diseases.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Ongoing technological innovations have significantly enhanced the precision and efficiency of screening techniques. Moreover, increased awareness about the benefits of early disease detection has led to a greater emphasis on preventive healthcare practices. The aging global population also contributes to demand growth, as the prevalence of age-related conditions that require regular blood screening rises.

In addition, rising global healthcare expenditures support the adoption of advanced technologies and services within blood screening, as healthcare providers seek to implement the latest and most effective diagnostic tools. These factors collectively fuel the growth and development of the blood screening market, highlighting its role in proactive healthcare strategies aimed at improving patient outcomes and public health.

Technology Segmentation Insights:

Nucleic Acid Amplification Tests (NAT) led the blood screening market, capturing a revenue share of 41.2% in 2024. The high demand for NAT is attributed to the increasing prevalence of infectious diseases, such as HIV and hepatitis, which require accurate and rapid testing that NAT provides. NAT tests are known for their high sensitivity and specificity, enabling them to detect even low levels of viral loads that traditional methods may not identify. The rising demand for early disease diagnosis and monitoring further propels the adoption of NAT. Technological improvements in amplification techniques also enhance the speed and efficiency of these tests, making them more suitable for use in clinical settings.

Next Generation Sequencing (NGS) is expected to grow at a CAGR of 16.5% over the forecast period. This technology has transformed genomic analysis by dramatically lowering sequencing costs while increasing accuracy. NGS allows for comprehensive profiling of genetic mutations, which is essential for personalized medicine and targeted therapies. Additionally, NGS’s ability to process multiple samples simultaneously increases laboratory throughput, making it an appealing choice for healthcare providers. The continuous advancements in NGS technologies ensure their relevance in applications such as early disease detection and monitoring, which supports market growth.

Overall, the development and adoption of advanced blood screening technologies like NAT and NGS drive the market’s expansion, underscoring their importance in delivering accurate, timely, and personalized healthcare solutions.

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

#Blood Screening Market Analysis #Blood Screening Market Trends #Blood Screening Market Growth

0 notes

marketstudyreport · 5 days ago

Text

Blood Screening Market Strategies With Forecast Till 2030

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Technology Segmentation Insights:

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

#Blood Screening Market Analysis #Blood Screening Market Trends #Blood Screening Market Growth

0 notes

businessmarketreports · 6 days ago

Text

An Overview of Next Generation Sequencers Market: Trends and Insights

The Next-Generation Sequencers (NGS) market is witnessing rapid growth, driven by advancements in sequencing technology, declining costs, and increasing applications across healthcare, research, and agriculture. NGS enables high-throughput DNA sequencing, allowing for a more comprehensive analysis of genomes, transcriptomes, and epigenomes.

Buy Full Report for More Insights on the Next Generation Sequencers Market Forecast Download a Free Sample Report

This market encompasses various components, including instruments, software, and reagents, catering to a wide array of end-users, such as hospitals, research institutes, and biotechnology firms.

1. Market Overview

Market Size and Growth: The NGS market has shown robust growth due to rising demand for genomic analysis in personalized medicine, cancer research, and genetic diagnostics. Increasing adoption in clinical settings, along with advancements in technology, has driven accessibility and expanded market reach.

Regional Trends: North America and Europe currently dominate the market due to high healthcare expenditures, advanced infrastructure, and a significant focus on research and development. Meanwhile, Asia-Pacific is emerging as a promising market due to rising healthcare investments and increasing adoption of genomic medicine.

Key Applications: The major applications for NGS include oncology, infectious disease diagnostics, reproductive health, and hereditary disease screening, along with applications in agriculture and environmental studies.

2. Key Trends in the NGS Market

Declining Sequencing Costs: The costs of sequencing have significantly dropped since the advent of NGS technologies. The "thousand-dollar genome" has become a reality, making genetic testing more affordable and accessible, particularly in research and clinical diagnostics.

Shift Towards Clinical Applications: There is a growing demand for NGS in clinical settings, particularly in oncology for tumor profiling, hereditary disease detection, and pharmacogenomics. Clinical applications are gaining traction due to their potential for precision medicine, helping tailor treatments to individual genetic profiles.

Focus on Cancer Research: Oncology remains a major application area for NGS, as it enables detailed cancer genome analysis, leading to better understanding of mutations and tumor behavior. This technology supports both research and diagnostic applications, fueling demand among pharmaceutical companies and research institutes focused on oncology.

Rise of Liquid Biopsies: NGS is widely used in liquid biopsies, which offer a non-invasive method for cancer detection and monitoring by analyzing cell-free DNA (cfDNA) from blood samples. Liquid biopsies are gaining popularity as they allow real-time monitoring of tumor progression and treatment efficacy, reducing the need for invasive procedures.

Emergence of Long-Read Sequencing: Long-read sequencing technologies, such as those offered by Pacific Biosciences and Oxford Nanopore, are gaining traction due to their ability to provide more comprehensive genomic insights. These technologies are particularly valuable in detecting structural variants and resolving complex genomic regions.

Development of Companion Diagnostics: NGS-based companion diagnostics, used to determine the efficacy and safety of a specific drug for a targeted patient group, are expanding. These diagnostics guide treatment decisions in oncology, particularly for identifying biomarkers associated with certain therapies.

3. Market Segmentation

By Product: The NGS market includes sequencers, software, consumables, and services. Consumables, including reagents and kits, constitute the largest segment due to repeated purchases. However, software solutions are gaining traction as data analysis and interpretation become more complex.

By Technology:

Whole Genome Sequencing (WGS): WGS provides a comprehensive view of the entire genome, making it suitable for research and complex disease studies.

Targeted Sequencing: Targeted sequencing is cost-effective and focuses on specific regions of interest, widely used in oncology and clinical diagnostics.

RNA Sequencing: RNA sequencing enables transcriptome analysis and is valuable in cancer research, gene expression studies, and drug discovery.

Exome Sequencing: Exome sequencing, which targets protein-coding regions, is a more affordable alternative to WGS and is commonly used for diagnosing genetic disorders.

By Application: The NGS market serves several applications, including oncology, infectious disease diagnosis, reproductive health, genetic screening, and forensic analysis. Oncology holds the largest share, while infectious disease applications, particularly in tracking pathogens and outbreaks, are rapidly growing.

By End User: The primary end-users include academic and research institutions, hospitals and clinics, pharmaceutical and biotechnology companies, and government agencies. Hospitals and clinics are showing increasing demand as NGS technology moves from research into clinical diagnostics.

4. Key Drivers and Challenges

Drivers:

Increased Demand for Precision Medicine: The trend toward personalized medicine is a major driver, as NGS allows for tailored treatments based on genetic profiles, improving treatment outcomes.

Growing Investment in Genomic Research: Governments, healthcare institutions, and private companies are heavily investing in genomic research and infrastructure to support NGS applications across various fields.

Expansion of Genetic Screening Programs: Many countries are implementing large-scale genetic screening programs for early detection of genetic disorders and hereditary cancers, boosting demand for NGS.

Challenges:

Data Management and Analysis Complexity: The high volume of data generated by NGS requires advanced bioinformatics solutions for analysis, interpretation, and storage. This creates a need for skilled personnel and sophisticated software.

Regulatory and Ethical Concerns: The regulatory landscape for NGS is evolving, and concerns regarding data privacy and ethical issues are prevalent. Obtaining regulatory approval for clinical NGS applications can be time-consuming.

High Initial Investment: Although sequencing costs have decreased, the initial investment required for NGS platforms and bioinformatics infrastructure remains high, limiting adoption in resource-constrained regions.

5. Competitive Landscape

The NGS market is highly competitive, with established players as well as new entrants focusing on niche applications. Key players are investing in research and development, collaborations, and acquisitions to strengthen their market positions and expand product portfolios.

Illumina, Inc.: Illumina is the market leader, with a dominant position in sequencing instruments and consumables. Its sequencers, including the NovaSeq and NextSeq series, are widely used in research and clinical settings.

Thermo Fisher Scientific, Inc.: Known for its Ion Torrent platform, Thermo Fisher focuses on providing affordable, high-throughput sequencing solutions, with applications ranging from cancer research to infectious disease diagnostics.

Pacific Biosciences: PacBio specializes in long-read sequencing technology, particularly valuable for applications that require high accuracy in structural variant detection. Its Sequel system is popular among researchers in complex genomics.

Oxford Nanopore Technologies: Oxford Nanopore offers portable, real-time sequencing devices like the MinION and PromethION, which are particularly useful for field-based applications and rapid sequencing needs.

BGI Group: Based in China, BGI is a major player in genome sequencing services and provides a range of sequencers tailored for research and clinical applications. Its focus on affordability has helped it gain traction in emerging markets.

Qiagen N.V.: Qiagen provides NGS sample preparation and bioinformatics solutions, with a particular emphasis on clinical diagnostics. Its GeneReader NGS System is aimed at making NGS more accessible in clinical labs.

Agilent Technologies: Agilent offers NGS target enrichment and analysis solutions, focusing on workflows for oncology and hereditary disease testing.

6. Future Outlook

Advancements in Data Analysis Tools: Continued improvements in bioinformatics and artificial intelligence are expected to streamline data interpretation, making NGS more accessible to clinical users and reducing the time required for analysis.

Rise of Multi-Omics Approaches: Multi-omics, which combines genomics with proteomics, transcriptomics, and metabolomics, is expected to enhance the understanding of complex diseases. NGS will play a key role in integrating genomic data with other molecular insights.

Increased Focus on Rare Disease Research: NGS enables the identification of mutations associated with rare genetic disorders, facilitating research and development of targeted therapies. This area is likely to see continued growth, especially as pharmaceutical companies invest in precision medicine.

Expansion of Direct-to-Consumer (DTC) Testing: DTC genetic testing is gaining popularity, and as NGS becomes more affordable, companies may offer more comprehensive and affordable sequencing-based consumer tests.

Development of Point-of-Care Sequencing: Point-of-care NGS devices, offering rapid and portable sequencing capabilities, could find applications in emergency rooms and remote locations, particularly for infectious disease diagnosis.

Conclusion

The NGS market is positioned for substantial growth, driven by its expanding role in clinical diagnostics, advancements in sequencing technology, and increasing affordability. Applications in cancer research, infectious disease detection, and reproductive health are set to grow as the technology becomes more integrated into healthcare systems worldwide. However, challenges such as data complexity and regulatory hurdles will require ongoing innovation in bioinformatics and clear guidelines for clinical use. As technology advances, NGS has the potential to become a routine tool in personalized medicine, facilitating earlier diagnosis, better treatments, and improved patient outcomes across a range of medical fields.

#Next-Generation Sequencers (NGS) market

0 notes

farmacuticals · 13 days ago

Text

Competitive Landscape and Key Players in SNP Genotyping Market

The SNP genotyping and analysis market is witnessing remarkable growth, driven by advancements in genomics and an increasing focus on personalized medicine. SNP (single nucleotide polymorphism) genotyping identifies variations in a single nucleotide in a genome, aiding in the study of genetic predispositions to various diseases, drug responses, and genetic traits. This market includes the technologies, tools, and services used to genotype SNPs and conduct analysis, which has widespread applications in research, diagnostics, and drug development. The demand for SNP genotyping and analysis is particularly high in the fields of oncology, pharmacogenomics, and agricultural research, as it enables deeper insights into genetic variations and their impact on individual and population-level health outcomes.

The SNP Genotyping and Analysis Market Size was projected to reach $13.7 billion (USD billion) in 2022 based on MRFR analysis. It is anticipated that the market for SNP genotyping and analysis will increase from 15.11 billion USD in 2023 to 36.6 billion USD in 2032. During the forecast period (2024-2032), the SNP Genotyping and Analysis Market is anticipated to develop at a CAGR of approximately 10.33%.

SNP Genotyping and Analysis Market Share

The SNP genotyping and analysis market share is primarily held by leading companies like Illumina, Thermo Fisher Scientific, and Bio-Rad Laboratories, which offer state-of-the-art genotyping tools, reagents, and software solutions. These companies dominate the market due to their advanced platforms, broad research capabilities, and established partnerships with research and clinical institutions. New market entrants, however, are gaining a foothold by focusing on cost-effective, high-throughput genotyping solutions. The market share is also geographically diverse, with North America and Europe holding prominent shares due to extensive research funding and a large base of biotech companies, while Asia-Pacific is rapidly growing due to expanding healthcare and research infrastructure.

SNP Genotyping and Analysis Market Analysis

SNP genotyping and analysis market analysis indicates significant growth potential due to the rising prevalence of chronic diseases and the increasing demand for genomic data in clinical and research settings. The analysis also shows that innovations in high-throughput sequencing and bioinformatics are facilitating more efficient, cost-effective SNP genotyping. Technologies like microarray analysis and next-generation sequencing (NGS) are key drivers, providing rapid and accurate SNP data at a fraction of traditional costs. This market analysis highlights the impact of growing awareness of genetic testing among patients and healthcare providers, as well as increasing investments by governments and private entities in genomic research. The focus on personalized medicine, where treatments are tailored to individual genetic profiles, is expected to drive continuous demand in the SNP genotyping and analysis market.

SNP Genotyping and Analysis Market Trends

Key SNP genotyping and analysis market trends include the adoption of automation and AI in genomics. AI-powered data analysis helps interpret large datasets generated by SNP genotyping, enabling faster and more accurate insights into genetic associations. Another trend is the increased use of SNP genotyping in non-invasive prenatal testing (NIPT) and newborn screening, which has become an essential aspect of early disease diagnosis and prevention. Furthermore, the integration of genotyping and bioinformatics platforms enables researchers to conduct more comprehensive analyses, streamlining the identification of disease-related SNPs. The growing interest in consumer genomics, where individuals can gain insights into their ancestry and health risks through direct-to-consumer (DTC) testing kits, is also impacting the SNP genotyping and analysis market.

Reasons to Buy the Reports

Market Insights and Forecasts: Detailed projections on the SNP genotyping and analysis market, including future opportunities and growth drivers.

Competitive Landscape: Comprehensive information on market share and strategic positioning of key players, enabling informed decision-making.

Technological Trends: Insights into the latest technological advancements, such as AI integration, next-generation sequencing, and bioinformatics tools in SNP genotyping.

Regional Analysis: Regional breakdowns and growth potential insights to help investors and companies identify high-opportunity areas globally.

Personalized Medicine Focus: Analysis of the expanding role of SNP genotyping in personalized medicine, highlighting its applications in oncology, pharmacogenomics, and genetic testing.

Recent Developments

Recent developments in the SNP genotyping and analysis market reflect a focus on expanding applications and improving technology. In 2023, Thermo Fisher Scientific launched a new NGS-based genotyping platform designed for high-accuracy pharmacogenomic research, enhancing its utility in personalized medicine. Illumina introduced a cost-effective array platform targeting SNP genotyping for agricultural genomics, providing a tailored solution for crop and livestock breeding. Additionally, Bio-Rad Laboratories announced a strategic collaboration to integrate its genotyping software with AI-powered bioinformatics tools, improving analysis speed and accuracy. Advancements in point-of-care (POC) genotyping devices have also been significant, allowing for rapid SNP analysis in clinical settings and contributing to the increased demand in the SNP genotyping and analysis market.

Related repots:

medical equipment rental market

medical radiation shielding market

membrane filtration market

oral solid dosage pharmaceutical market

0 notes

ankitblogs0709 · 17 days ago

Text

Drug Discovery And Development Laboratory Services Market Forecast and Analysis Report (2023-2032)

The global demand for Drug Discovery And Development Laboratory Services was valued at USD 16845.8million in 2022 and is expected to reach USD 50819.0 Million in 2030, growing at a CAGR of 14.80% between 2023 and 2030.

Drug discovery and development laboratory services are essential to the pharmaceutical and biotech industries, supporting the journey from initial research to approved medications. These specialized laboratories conduct a wide range of activities, including target identification, assay development, high-throughput screening, and lead optimization, to identify potential drug candidates. Additionally, they provide essential preclinical testing, pharmacokinetics, toxicology studies, and bioanalytical services to evaluate the safety, efficacy, and pharmacological profiles of compounds before clinical trials. With increasing complexity in drug development, such as the rise of biologics and precision medicine, demand for specialized laboratory services has surged, driving advancements in automation, data analytics, and high-tech equipment. These services play a critical role in accelerating the drug discovery timeline, improving the success rates of therapeutic candidates, and helping companies navigate stringent regulatory requirements more effectively, ultimately contributing to faster and more efficient drug development pipelines.

The drug discovery and development laboratory services market presents several growth opportunities, driven by advancements in biotechnology, personalized medicine, and the increasing demand for efficient drug development processes. Here are some key growth areas:

Biologics and Biosimilars: The rise in biologics and biosimilars has created demand for specialized lab services, including bioassays, molecular biology, and immunogenicity testing, as companies seek reliable support for the development of complex biological drugs.

Precision and Personalized Medicine: The shift towards personalized medicine requires services like genetic profiling, biomarker discovery, and cell-based assays, creating opportunities for labs that offer these niche capabilities to support targeted therapies.

AI and Automation in Drug Discovery: Artificial intelligence and automation have become critical for enhancing drug discovery efficiency, allowing laboratories to conduct high-throughput screening and data analysis faster. Labs investing in AI-based platforms and robotic systems can offer faster, cost-effective services, making them attractive to pharmaceutical clients.

Increased Outsourcing by Pharmaceutical Companies: Pharmaceutical and biotech companies increasingly outsource drug development stages to specialized labs to reduce costs and focus on core competencies, creating significant demand for third-party laboratory services.

Growing Demand for Toxicology and Safety Testing: Regulatory bodies emphasize rigorous safety assessments, fueling demand for toxicology, pharmacokinetics, and bioanalytical services that ensure compliance and drug safety at every development stage.

Expansion in Emerging Markets: Emerging markets in Asia-Pacific, Latin America, and Eastern Europe offer growth opportunities due to rising healthcare investments, lower operational costs, and an expanding pharmaceutical sector, prompting global labs to establish facilities in these regions.

Collaborations with Academic and Research Institutions: Partnerships with academic institutions facilitate early-stage research and foster innovation, providing labs with fresh insights and potentially lucrative opportunities to collaborate on cutting-edge projects.

Development of Advanced Analytical Techniques: Techniques like CRISPR, next-generation sequencing, and advanced imaging provide expanded services for drug discovery, allowing labs to offer high-precision solutions for identifying drug candidates with improved accuracy.

Access Complete Report - https://www.credenceresearch.com/report/drug-discovery-development-laboratory-services-market

Key Players

General Electric (U.S.)

Eurofins Scientific (U.S.)

PPD Inc. (U.S.)

Syngene International Limited (India)

Wuxi AppTec (China)

Frontage Labs (U.S.)

Galapagos NV (Belgium)

Aurigene Discovery Technologies (India)

Genscript (U.S.)

Domainex (U.K.)

WIL Research Laboratories LLC (U.S.)

Shanghai Medicilon, Inc. (China)

Labcorp Drug Development (U.S.)

Jubilant Biosys Ltd. (India)

Evotec (Germany)

Shanghai ChemPartner (China)

Charles River Laboratories (U.S.)

Merck & Co. Inc. (U.S.)

Thermo Fisher Scientific Inc. (U.S.)

The drug discovery and development laboratory services market is undergoing rapid transformation, driven by several innovative trends that are reshaping the way drugs are researched, tested, and brought to market. Here are some key trends:

Artificial Intelligence and Machine Learning Integration: AI and ML are revolutionizing drug discovery by accelerating processes like target identification, lead optimization, and predictive modeling. These technologies allow laboratories to analyze vast datasets quickly, increasing the accuracy of drug target selection and reducing discovery timelines.

High-Throughput Screening Automation: Automation in high-throughput screening (HTS) enables labs to test thousands of compounds simultaneously. Robotic systems and automated workflows enhance efficiency, making HTS faster, more reliable, and cost-effective, which is essential for identifying potential drug candidates more quickly.

CRISPR and Gene Editing Technologies: CRISPR-based techniques have become instrumental in studying disease models and developing targeted therapies. These technologies allow labs to edit genes with precision, making them invaluable for identifying novel drug targets and accelerating preclinical research.

Advances in Biomarker Discovery: Biomarker discovery is increasingly central to developing targeted and personalized therapies. Advances in proteomics, genomics, and metabolomics enable labs to identify biomarkers more accurately, supporting the development of treatments tailored to specific patient populations.

Lab-on-a-Chip and Microfluidics: Miniaturization with lab-on-a-chip and microfluidic technologies enables precise control of experimental conditions on a small scale, reducing reagent use and allowing rapid, low-cost testing. These innovations are transforming assays and early-stage testing, increasing lab efficiency.

3D Cell Cultures and Organoids: Traditional 2D cell cultures are increasingly being replaced by 3D cultures and organoids, which provide more realistic models of human tissues. These models improve the accuracy of preclinical testing, reducing reliance on animal models and enhancing insights into drug efficacy and toxicity.

In Silico Drug Design and Virtual Screening: Computational approaches like in silico modeling and virtual screening allow labs to simulate interactions between compounds and targets, reducing the need for extensive physical testing. These tools can rapidly narrow down viable drug candidates, saving time and resources.

Expansion of Outsourcing and Partnerships: Many pharmaceutical companies are outsourcing parts of their drug discovery and development processes to specialized labs, fostering innovation and efficiency. Strategic partnerships with CROs (Contract Research Organizations) are becoming common, allowing companies to access expertise and advanced technologies without heavy investments.

Real-World Data Integration: The use of real-world data (RWD), including patient records and post-market surveillance, helps labs and pharmaceutical companies gain insights into drug safety and efficacy in diverse populations. RWD integration enables data-driven decisions that improve clinical trial design and outcomes.

Green Chemistry and Sustainable Practices: There is a growing emphasis on sustainability in drug development. Labs are adopting green chemistry principles, using eco-friendly solvents, and reducing waste to minimize their environmental impact, aligning with broader industry goals for sustainability.

Segmentation

By Bioanalytical Testing Services:

Pharmacokinetics (PK) and Pharmacodynamics (PD) Studies

By Drug Metabolism and Pharmacokinetics (DMPK) Services:

Metabolite Profiling

Plasma Protein Binding Studies

By Pharmaceutical Chemistry Services:

Synthetic Chemistry

Analytical Chemistry

By Cell Line Development and Engineering:

Cell Line Characterization

Cell Line Engineering

By Clinical Trial Services:

Clinical Laboratory Testing

Central Laboratory Services

By Genomic Services:

Genomic Sequencing

Genomic Data Analysis

By Proteomic Services:

Protein Expression and Characterization

Proteomic Profiling

By Pharmacovigilance and Safety Testing:

Adverse Event Monitoring

Safety Pharmacology Studies

By Quality Control and Assurance:

GMP (Good Manufacturing Practice) Testing

Quality Control Testing

By Technology Platforms:

Advanced Analytics

High-Throughput Screening (HTS)

Browse the full report – https://www.credenceresearch.com/report/drug-discovery-development-laboratory-services-market

Phone: +91 6232 49 3207

Email: [email protected]

Website: https://www.credenceresearch.com

0 notes

latestmarketresearchnews · 19 days ago

Text

Blood Screening Market Size, Share & Trends Analysis Report By 2030

The global blood screening market was valued at USD 3.40 billion in 2024, and it is expected to grow at a compound annual growth rate (CAGR) of 11.9% from 2025 to 2030. The market's rapid expansion is primarily driven by the increasing number of blood donations worldwide, which necessitates stringent screening protocols to ensure the safety of blood and detect transfusion-transmissible infections. This growth is further fueled by advancements in technology, particularly in automation and molecular platforms, which enhance the accuracy and efficiency of blood screening processes. Additionally, the rising prevalence of infectious diseases, combined with government initiatives aimed at promoting blood safety, is contributing to the market's upward trajectory. Growing public awareness about the importance of safe blood transfusions also plays a key role in market growth.

Blood screening is a critical medical procedure that involves analyzing blood samples to detect various health conditions and abnormalities. It provides vital insights into an individual's health, allowing for the early detection, prevention, and management of diseases. The screening process typically involves evaluating blood cell counts, identifying infectious agents like viruses and bacteria, and measuring levels of chemicals such as cholesterol and glucose. The significance of blood screening lies in its ability to help healthcare professionals identify potential health problems before symptoms appear. This is crucial in diagnosing conditions like anemia, diabetes, infections, and cardiovascular diseases.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Technological advancements continue to improve the precision and efficiency of blood screening methods. At the same time, increasing awareness about the importance of early disease detection promotes the adoption of preventive healthcare measures. Another contributing factor to the market's growth is the aging global population, which is associated with a higher prevalence of diseases that require blood screening. Rising healthcare expenditures around the world also support the adoption of advanced technologies and services in the blood screening field. Together, these factors drive the ongoing growth and evolution of the blood screening market, highlighting its essential role in proactive healthcare strategies aimed at improving patient outcomes and public health.

Product Segmentation Insights:

In 2024, reagents led the blood screening market, accounting for the largest revenue share of 73.4%. Reagents are critical components in diagnostic tests, providing the chemical, biological, or immunological substances required to trigger specific reactions that yield accurate test results. The growing demand for highly specific and precise blood analyses has driven the development of innovative reagent formulations that enhance the performance of diagnostic tests. Reagents are also cost-effective, making them widely accessible, which contributes to their dominant market position.

The instruments segment is expected to experience the fastest growth, with a projected CAGR of 10.8% over the forecast period. This growth is attributed to technological advancements and the increasing demand for reliable diagnostic solutions. Modern blood screening instruments are designed to improve both accuracy and efficiency, addressing the need for rapid diagnostics in healthcare settings. Innovations such as high-throughput analyzers and point-of-care testing devices have improved the usability and accessibility of blood testing. Despite challenges such as high costs and the reusable nature of some devices, continuous technological development is expected to drive sustained growth in this segment. Healthcare providers are increasingly seeking dependable and efficient tools for blood analysis, and the advancements in instruments are expected to meet these evolving needs.

In summary, the global blood screening market is poised for strong growth due to factors such as increasing blood donations, technological innovations, rising healthcare expenditures, and greater public awareness. The market will continue to evolve, driven by a combination of product developments in reagents and instruments, along with a growing focus on preventive healthcare and early disease detection.

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

#Blood Screening Market Forecast #Blood Screening Market Overview #Blood Screening Market Size #Blood Screening Industry

0 notes

researchreportinsight · 19 days ago

Text

Blood Screening Industry Size & Share | Statistics Report 2030

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Product Segmentation Insights:

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

#Blood Screening Market Forecast #Blood Screening Market Overview #Blood Screening Market Size #Blood Screening Industry

0 notes

amrutatbrc1 · 27 days ago

Text

Microplate Instrumentation And Supplies Market : Technology Advancements, Industry Insights, Trends And Forecast 2033

The microplate instrumentation and supplies global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Microplate Instrumentation And Supplies Market, 2024The microplate instrumentation and supplies global market report 2024

Market Size -

The microplate instrumentation and supplies market size has grown strongly in recent years. It will grow from $6.49 billion in 2023 to $6.96 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to expansion of biotech and pharmaceutical companies, increasing the need for drug discovery and development, increasing the need for high-throughput screening tools, increasing investment from government agencies, and rising automation. The microplate instrumentation and supplies market size is expected to see strong growth in the next few years. It will grow to $9.26 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to the growing demand for point-of-care testing and diagnostics, investments in research and development (R&D), rising frequency of chronic diseases, growing emphasis on genetics, and rising demand for personalized medicine. Major trends in the forecast period include integration of artificial intelligence and machine learning, adoption of 3D cell cultures and organoids in research, integration of cloud computing and internet of things (IoT) in microplates, integration of robotics, and developments in drug discovery and life science.

Order your report now for swift delivery @

The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Market Overview

Market Drivers -The rising demand for personalized medicine is anticipated to drive the growth of the microplate instrumentation and supplies market in the near future. Personalized medicine, or precision medicine, is an approach that tailors treatment and healthcare strategies to individual patients based on their unique genetic, environmental, and lifestyle factors. This demand is fueled by the growing incidence of chronic conditions, heightened consumer awareness and expectations, and cost-effectiveness. Microplate instrumentation and supplies are essential in personalized medicine as they enable precise, high-throughput testing and analysis of biological samples, which is crucial for customizing medical treatments based on each patient's distinct genetic, biomolecular, and cellular profiles. For instance, according to the Personalized Medicine Coalition Reports in February 2024, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for patients with rare diseases in 2023, a significant increase from the six approvals in 2022. Therefore, the rising demand for personalized medicine is propelling the growth of the microplate instrumentation and supplies market.

Market Trends -

Major companies operating in the microplate instrumentation and supplies market are focused on developing innovative products, such as EDR technology-based microplate readers, to improve assay accuracy, increase throughput, and streamline laboratory workflows. EDR (Extended Dynamic Range) technology-based microplate readers are advanced instruments designed to enhance the range and sensitivity of detection in various assays, which is particularly useful in personalized medicine and other research applications. For instance, in February 2022, BMG LABTECH, a Germany-based company specializing in developing microplate readers, launched the new VANTAstar microplate reader. This product incorporates EDR technology, which allows for a dynamic range spanning over eight concentration decades in a single measurement. This feature simplifies the process by eliminating the need for manual gain adjustments, as each plate is automatically read with optimal sensitivity settings.

The microplate instrumentation and supplies market covered in this report is segmented –

1) By Product Type: Microplate Readers, Microplate Washers, Microplate Dispensers, Microplate Accessories, Other Accessories 2) By Sales Channel: Direct Sales, Indirect Sales 3) By End-User Industries: Pharmaceuticals, Food And Beverages, Chemicals And Polymer, Other End-User Industries

Get an inside scoop of the microplate instrumentation and supplies market, Request now for Sample Report @

Regional Insights -

North America was the largest region in the microplate instrumentation and supplies market in 2023. The regions covered in the microplate instrumentation and supplies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies -

Major companies in the market are Thermo Fisher Scientific Inc., Danaher Corporation, The Merck Group, Corning Incorporated, Agilent Technologies Inc., Lonza Group AG, Beckman Coulter Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Eppendorf AG, Promega Corporation, Hamilton Company, Molecular Devices LLC, Analytik Jena AG, Biochrom Ltd., OriGene Technologies Inc., Berthold Technologies GmbH & Co. KG, BMG LABTECH GmbH, BrandTech Scientific Inc., Hudson Robotics Inc., Labnet International Inc.

Table of Contents

1. Executive Summary 2. Microplate Instrumentation And Supplies Market Report Structure 3. Microplate Instrumentation And Supplies Market Trends And Strategies 4. Microplate Instrumentation And Supplies Market – Macro Economic Scenario 5. Microplate Instrumentation And Supplies Market Size And Growth ….. 27. Microplate Instrumentation And Supplies Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [email protected]

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

0 notes

priyanshisingh · 1 month ago

Text

Protein Stability Analysis Market Trends and Opportunities: Global Outlook (2023-2032)

The global Protein Stability Analysis Market is poised for substantial growth, with its market size projected to expand from USD 2,405 million in 2024 to USD 5,765.96 million by 2032, reflecting a robust compound annual growth rate (CAGR) of 11.55% during the forecast period.

The protein stability analysis market is witnessing significant growth, driven by its critical role in biopharmaceutical development, drug discovery, and research in molecular biology. Protein stability refers to the ability of a protein to maintain its structure and function under various environmental conditions, such as temperature, pH, and chemical stress. Understanding protein stability is essential in the development of biologics, including therapeutic proteins, antibodies, and vaccines, as unstable proteins can lead to reduced efficacy and increased risk of immunogenicity. The growing demand for biopharmaceuticals, coupled with the need for high-quality protein formulations, is fueling the market for protein stability analysis. Additionally, advancements in protein engineering, the rise of personalized medicine, and increasing research in areas like proteomics and structural biology are contributing to the expansion of the market.

Various techniques, including differential scanning calorimetry (DSC), dynamic light scattering (DLS), fluorescence spectroscopy, and circular dichroism (CD), are employed for protein stability analysis. These methods help in assessing protein unfolding, aggregation, and thermal stability, providing valuable insights into protein behavior under stress. Automation and high-throughput screening technologies are also gaining traction, enabling more efficient analysis, particularly in pharmaceutical research and development.

Here are the key drivers propelling the growth of the protein stability analysis market:

Rising Demand for Biopharmaceuticals: The increasing use of biologics, including therapeutic proteins, monoclonal antibodies, and vaccines, is a major driver for protein stability analysis. Biopharmaceutical companies rely heavily on ensuring the stability of proteins during development, manufacturing, and storage to maintain product efficacy and safety. As the demand for biologics continues to rise globally, the need for reliable protein stability analysis is growing in tandem.

Advancements in Protein Engineering: Innovations in protein engineering and design, particularly in the development of more stable and effective therapeutic proteins, are fueling the need for advanced protein stability analysis techniques. Researchers are increasingly exploring new methods to modify protein structures and improve their stability, driving demand for robust analytical tools and technologies.

Increasing Focus on Drug Discovery and Development: Protein stability plays a crucial role in drug discovery, especially in screening and optimizing candidate molecules. Pharmaceutical and biotechnology companies are investing in protein stability analysis to enhance the drug development process, reduce the risk of failures, and ensure higher success rates during clinical trials. This focus is especially important for personalized medicine, where stable protein formulations are essential for targeted therapies.

Growth in Proteomics and Structural Biology Research: The expanding field of proteomics and structural biology is driving demand for protein stability analysis, as researchers seek to better understand protein folding, aggregation, and interactions under various conditions. As these fields grow, there is an increasing need for sophisticated analytical tools to study protein structures and dynamics, making protein stability analysis essential for advancing research.

Key Player Analysis:

Thermo Fisher Scientific Inc.

Agilent Technologies, Inc.

PerkinElmer, Inc.

Waters Corporation

GE Healthcare (now part of Cytiva)

Shimadzu Corporation

Malvern Panalytical Ltd. (Spectris PLC)

Bio-Techne Corporation

Horiba, Ltd.

Unchained Labs

More About Report- https://www.credenceresearch.com/report/protein-stability-analysis-market

The future outlook for the protein stability analysis market is highly promising, with growth driven by advancements in biopharmaceutical development, personalized medicine, and innovations in analytical technologies. As the demand for biologics, such as therapeutic proteins, antibodies, and vaccines, continues to rise, the need for more precise and reliable protein stability analysis will only intensify. Biopharmaceutical companies will increasingly rely on these analyses to ensure the efficacy, safety, and shelf life of their products, particularly as the pipeline of biologic drugs grows globally.

Technological advancements are expected to play a key role in shaping the future of this market. Emerging tools like high-throughput screening, automation, and artificial intelligence (AI) integration are likely to enhance the speed and accuracy of protein stability testing. These innovations will help streamline the analysis process, reduce costs, and improve decision-making in drug discovery and development. Furthermore, new and improved techniques, such as isothermal titration calorimetry (ITC), hydrogen-deuterium exchange mass spectrometry (HDX-MS), and advanced fluorescence spectroscopy, will continue to offer deeper insights into protein dynamics, folding, and stability.

Geographically, the Asia-Pacific region is poised for significant growth in the coming years, fueled by expanding biopharmaceutical industries in countries like China, India, and Japan. Increasing investments in life sciences research and growing collaborations between academic institutions and industry players will further accelerate market expansion in this region.

Additionally, as the focus on precision medicine and tailored therapies grows, the development of stable protein formulations for specific patient populations will create new opportunities in the protein stability analysis market. Regulatory support and initiatives promoting the use of biologics in healthcare systems will further drive market growth.

Segmentations:

By Product

Reagents and Assay Kits

Instruments

Consumables and Accessories

Software

Service

By Technique

Chromatography

Spectroscopy

Differential Scanning Calorimetry (DSC)

Differential Scanning Fluorimetry (DSF)

Dynamic Light Scattering (DLS)

Others

By End User

Pharmaceutical & Biotechnology Companies

Contract Research Organizations

Academic Research Institutes

Browse the full report – https://www.credenceresearch.com/report/protein-stability-analysis-market

Browse Our Blog: https://www.linkedin.com/pulse/protein-stability-analysis-market-global-8ycwf

Phone: +91 6232 49 3207

Email: [email protected]

Website: https://www.credenceresearch.com

0 notes

insightfulblogz · 3 days ago

Text

Protein Crystallization Market Opportunities, Statistics, COVID-19 Impact, and Forecast by 2032

Protein crystallization is a critical technique in structural biology, allowing scientists to visualize the three-dimensional structures of proteins at atomic resolution. By crystallizing proteins, researchers can better understand their functions, interactions, and mechanisms, aiding in the design of novel therapeutics. This process is essential in drug discovery, as detailed protein structures provide insights into potential drug-binding sites and facilitate the development of targeted treatments. Protein crystallization has applications across pharmaceuticals, biotechnology, and academia, contributing to major advancements in biological research and drug development.

The Protein Crystallization Market size was estimated at USD 1.20 billion in 2023 and is expected to reach USD 2.49 billion by 2032 at a CAGR of 8.45% during the forecast period of 2024-2032.

Future Scope

The future of protein crystallization lies in the advancement of automation, high-throughput screening, and microfluidic technologies. Automation will streamline the crystallization process, reducing the time and labor required for experimentation. High-throughput screening will allow for simultaneous crystallization trials, expediting the identification of optimal conditions. Additionally, microfluidic systems are expected to miniaturize and enhance crystallization setups, making it possible to work with scarce protein samples. These advancements will help researchers overcome the challenges of crystallizing complex proteins, broadening the scope of proteins available for study and accelerating drug discovery.

Trends

Current trends in protein crystallization include the rise of automated crystallization platforms, the use of X-ray free-electron lasers (XFELs), and the adoption of cryo-electron microscopy (cryo-EM) as a complementary tool. Automated systems increase reproducibility and efficiency, while XFELs enable researchers to capture high-resolution images of protein crystals without causing damage. Cryo-EM, often used in conjunction with crystallization, allows for the visualization of complex protein structures in near-native states. These trends are transforming protein crystallization and driving innovations in structural biology and pharmacology.

Applications

Protein crystallization has extensive applications in drug discovery, structural biology, and biotechnology. In drug discovery, crystallization is used to determine the structures of drug targets, aiding in the design of small molecules and biologics with high binding affinity. Structural biology relies on crystallization to elucidate protein functions and interactions, providing foundational knowledge for understanding diseases and developing new treatments. In biotechnology, protein crystallization supports the development of enzymes and biocatalysts for industrial applications, optimizing their performance for specific biochemical reactions.

Key Points

Protein crystallization enables visualization of protein structures, aiding drug discovery and structural biology.

Future advancements include automation, high-throughput screening, and microfluidic systems for enhanced efficiency.

Trends involve automated platforms, XFELs, and cryo-EM as complementary visualization tools.

Applications span drug discovery, structural biology, and biotechnology, supporting therapeutic and industrial research.

Critical for understanding disease mechanisms and developing targeted therapies.

Conclusion

Protein crystallization remains a cornerstone of structural biology and drug discovery, enabling scientists to unlock the molecular secrets of proteins. As new technologies advance the crystallization process, researchers will be able to tackle increasingly complex protein targets, paving the way for breakthroughs in disease treatment and therapeutic design. Protein crystallization will continue to drive scientific innovation, advancing our understanding of biology and supporting the development of next-generation drugs.

Read More Details: https://www.snsinsider.com/reports/protein-crystallization-market-3879

Akash Anand — Head of Business Development & Strategy

Email: [email protected]

Phone: +1–415–230–0044 (US) | +91–7798602273 (IND)

#Protein Crystallization Market #Protein Crystallization Market Size #Protein Crystallization Market Share #Protein Crystallization Market Growth

0 notes

industrynewsupdates · 1 month ago

Text

Genomics Market Business Growth, Opportunities and Forecast 2024-2030

The global genomics market size was valued at USD 32.65 billion in 2023 and is projected to witness a compound annual growth rate (CAGR) of 16.5% from 2024 to 2030.

The growth of genomics market is attributed to factors such as growing demand for gene therapy, personalized medicine, drug discovery, increasing cancer incidence, and a significant increase in demand for consumer genomics in recent years. Moreover, increasing number of joint ventures and partnerships amongst market players is also expected to have a positive impact on the genomics market growth. For instance, in June 2022, Illumina, Inc., and Allegheny Health Network signed a collaboration for effective evaluation of the impact of in-house Comprehensive Genomic Profiling (CGP) to leverage patient care.

Gather more insights about the market drivers, restrains and growth of the Genomics Market

The COVID-19 pandemic outbreak had posed challenges to applications of genomics technology in terms of research and therapeutics. Nevertheless, some niche applications were of great use to mankind during the pandemic situation to facilitate immediate attention for designing effective diagnostics, effective therapeutics and steps to curb the spread of COVID-19. For example, the viral genome mutational rate (~1-2 bases per month) was gauged for validity of PCR cycle was estimated to understand the efficacy of the re-purposed anti-viral treatments and thereby the vaccine development process was streamlined.

Many genomic surveillance programs were launched country wise to understand the dynamics of pandemic situation and to effective preventive measures. For instance, in December 2020, the Indian SARS-CoV-2 Genomics Consortium (INSACOG) was launched by the joint efforts of Department of Biotechnology (DBT), Ministry of Health, and ICMR with an aim to screen the genomic variations in the SARS-CoV-2 by sequencing technologies. Furthermore, country specific companies are providing consumer genomics services which is also expected to fuel the market size in coming years. One such company being Mapmygenome which is one of the pioneers in India offers DTC genomics services.

The increasing prevalence of inherited cancers is expected create a high demand for cancer genomics. The substantial understanding of human genome have targeted focus on use of various gene therapies for treatment of cancers by modern gene editing techniques such as CRISPR-Cas gene technology. For instance, in September 2022, a group of researchers at the University of California introduced the applications of precision genome editing agents for management of inherited retinal diseases (IRDs).

The development of high-throughput sequencing technologies such as Next-Generation Sequencing (NGS) and microarrays has generated massive amounts of genomic data. However, the rapid accumulation of this data from DNA sequencing and Electronic Health Records (EHRs) poses significant challenges and opportunities for the extraction of biologically or clinically relevant information. Phenome-wide association study (PheWAS) & genome-wide association study (GWAS) are helping researchers to study correlations between genotype and phenotype.

The market players are extensively working towards collaborations, expansions, acquisitions and huge capital investments to advance in research to understand rare diseases and to aid drug discovery. For instance, PacBio declares a collaboration with the Genomics England society for the utility of PacBio’s technology to detect genetic variation in unexplained rare disorders. The study is intended to re-sequence a selection of samples collected during Genomics England’s 100,000 genomes project to discover potential operational and clinical benefits of long-read sequencing for the identification of mutations associated with rare diseases.

Genomics Market Segmentation

Grand View Research has segmented the global genomics market based on application, technology, deliverables, end-use, and region:

Application & Technology Outlook (Revenue, USD Billion, 2018 - 2030)

• Functional Genomics

• Transfection

• Real-Time PCR

• RNA Interference

• Mutational Analysis

• SNP Analysis

• Microarray Analysis

• Epigenomics

• Bisulfite Sequencing

• Chromatin Immunoprecipitation (ChIP & ChIP-Seq)

• Methylated DNA Immunoprecipitation (MeDIP)

• High-Resolution Melt (HRM)

• Chromatin Accessibility Assays

• Microarray Analysis

• Pathway Analysis

• Bead-Based Analysis

• Microarray Analysis

• Real-time PCR

• Proteomics Tools (2-D PAGE; yeast 2-hybrid studies)

• Biomarker Discovery

• Mass Spectrometry

• Real-time PCR

• Microarray Analysis

• Statistical Analysis

• Bioinformatics

• DNA Sequencing

• Others

Technology Outlook (Revenue, USD Billion, 2018 - 2030)

• Sequencing

• PCR

• Flow Cytometry

• Microarrays

• Other technologies

Deliverables Outlook (Revenue, USD Billion, 2018 - 2030)

• Products

o Instruments/Systems/Software

o Consumables & Reagents

• Services

o NGS-based Services

o Core Genomics Services

o Biomarker Translation Services

o Computational Services

o Others

End-use Outlook (Revenue, USD Billion, 2018 - 2030)

• Clinical Research

• Academic & Government Institutes

• Hospitals & Clinics

• Pharmaceutical & Biotechnology Companies

• Other End Users

Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o U.K.

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o China

o India

o Japan

o South Korea

o Australia

o Thailand

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East & Africa

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global cell sorting market size was valued at USD 242.7 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2030.

• The global live cell imaging market size was valued at USD 2.48 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2030.

Key Companies & Market Share Insights

The market players operating in the genomics market are adopting product approval to increase the reach of their products in the market and improve the availability of their products & services in diverse geographical areas, along with expansion as a strategy to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.

Key Genomics Companies:

• Agilent Technologies

• Bio-Rad Laboratories, Inc.

• BGI Genomics

• Color Genomics, Inc.

• Danaher Corporation

• Eppendorf AG

• Eurofins Scientific

• F. Hoffmann-La Roche Ltd.

• GE Healthcare

• Illumina, Inc.

• Myriad Genetics, Inc.

• Oxford Nanopore Technologies

• Pacific Biosciences of California, Inc.

• QIAGEN N.V.

• Quest Diagnostics Incorporated

• Thermo Fisher Scientific, Inc.

• 23andMe, Inc.

Recent Development

• In November 2023, Fabric Genomics collaborated with DNAnexus and Oxford Nanopore Technologies for deployment of CLIA/CAP labs in pediatric and neonatal ICU’s. The labs will use Oxford Nanopore’s platforms to study genetic disorders in infants.

• In February 2023, Illumina, Inc. entered into a collaboration with African Centre of Excellence for Genomics of Infectious Diseases to start a training institute to increase genomic capabilities in African region

• In January 2023, SOPHiA GENETIC collaborated with the Memorial Sloan Kettering Cancer Center (MSK), a U.S. Cancer Center, to offer researchers and clinicians solutions to expand analytical and testing capabilities.

• In January 2023, Agilent Technologies, Inc. announced acquisition of Avida Biomed, a company that develops target enrichment workflows for clinical researchers utilizing NGS methods to study cancers.

• In April 2022, QIAGEN launched the Biomedical Knowledge Base in Europe, Japan, North America, and Australia to support data science applications in biotech companies

Order a free sample PDF of the Genomics Market Intelligence Study, published by Grand View Research.

#Genomics Market #Genomics Market size #Genomics Market share #Genomics Market analysis #Genomics Industry

0 notes